A synthetic cell-penetrating dominant-negative ATF5 peptide exerts anti-cancer activity against a broad spectrum of treatment resistant cancers

Georg Karpel-Massler\textsuperscript{1}, Basil A. Horst\textsuperscript{2}, Chang Shu\textsuperscript{1}, Lily Chau\textsuperscript{1}, Takashi Tsujiuchi\textsuperscript{3}, Jeffrey N. Bruce\textsuperscript{3}, Peter Canoll\textsuperscript{1}, Lloyd A. Greene\textsuperscript{1}, James M. Angelastro\textsuperscript{4}, Markus D. Siegelin\textsuperscript{1}

\textsuperscript{1} Department of Pathology & Cell Biology, Columbia University Medical Center, New York, New York, U.S.A.
\textsuperscript{2} Department of Dermatology, Columbia University Medical Center, New York, New York, U.S.A.
\textsuperscript{3} Department of Neurosurgery, Columbia University Medical Center, New York, New York, U.S.A.
\textsuperscript{4} Department of Molecular Biosciences, University of California, Davis School of Veterinary Medicine, Davis, California, U.S.A.

Lily Chau's present address is: Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York, U.S.A.

Running title: Peptide-based inhibition of ATF5 for cancer therapy

Keywords: ATF5, cell-penetrating peptide, apoptosis, Usp9X, ABT263.

Correspondence to:
Markus D. Siegelin, MD, Dr. med.
Department of Pathology & Cell Biology
Columbia University Medical Center
630 West 168\textsuperscript{th} Street, P&S Rm. 15-401
New York, NY 10032
\texttt{ms4169@cumc.columbia.edu}
Phone: 212- 305-1993

James M. Angelastro, PhD
Department of Molecular Biosciences,
University of California
One Shields Ave
Davis, CA 95616
\texttt{jmangelastro@ucdavis.com}
Phone: 530-752-1591
Financial support:
This work was supported by a scholarship from the Dr. Mildred Scheel foundation of the German Cancer Aid to GKM and American Brain Tumor Association, Translational Grant 2013 (ABTACU13-0098), the 2013 AACR-National Brain Tumor Society Career Development Award for Translational Brain Tumor Research (13-20-23-SIEG), NIH NINDS award K08NS083732 to MDS and NIH NINDS grant R01NS083795 to JMA and LAG.

Conflict of interests:
Columbia University, on behalf of inventors Drs. Angelastro and Greene, has been awarded United States patents US 0788326 “Methods for promoting apoptosis and treating tumor cells by inhibiting the expression or function of the transcription factor ATF5” and US 08158420 “Methods for inhibiting the differentiation of proliferative telencephalic cells in vitro by addition of ATF5”. Columbia University/University of California, Davis; Provisional patent application was filed, February 22, 2013 with U.S. Provisional Application Serial No. 61/768,390. “Compositions and Methods for Inhibiting Tumor Cells by Inhibiting the Transcription Factor ATF5.”
GKM, BAH, CS, LC, TT, JNB, PC and MDS declare no conflict of interest.

Statement of translational relevance:
Targeting treatment resistant malignancies remains a major challenge in oncology. In the present study, we introduce a novel therapeutic compound targeting Activating Transcription Factor 5 (ATF5) through utilization of a novel cell penetrating peptide, termed CP-d/n-ATF5-S1. CP-d/n-ATF5-S1 displays broad anti-cancer activity against glioblastoma, triple receptor negative breast cancer, prostatic carcinoma, pancreatic cancer, melanoma, non-small cell lung carcinoma and hematological malignancies. Notably, we provide evidence that these anti-neoplastic effects are not only observed in vitro, but are also seen in 6 different animal models of glioblastoma, melanoma, prostatic adenocarcinoma, triple-receptor negative breast cancer and pancreatic carcinoma without any detectable toxicity. Finally, CP-d/n-ATF5-S1 sensitizes tumor cells for BH3-mimetics and extrinsic apoptotic stimuli in vitro and in vivo. Taken together, CP-d/n-ATF5-S1 is a novel highly efficacious anti-cancer compound with minimal toxicity and potentially warrants clinical testing in patients.
Abstract

Purpose: Despite significant progress in cancer research many tumor entities still have an unfavorable prognosis. Activating Transcription Factor 5 (ATF5) is up-regulated in various malignancies and promotes apoptotic resistance. We evaluated the efficacy and mechanisms of the first described synthetic cell-penetrating inhibitor of ATF5 function, CP-d/n-ATF5-S1.

Experimental Design: Preclinical drug testing was performed in various treatment-resistant cancer cells and in vivo xenograft models.

Results: CP-d/n-ATF5-S1 reduced the transcript levels of several known direct ATF5 targets. It depleted endogenous ATF5 and induced apoptosis across a broad panel of treatment refractory cancer cell lines, sparing non-neoplastic cells. CP-d/n-ATF5-S1 promoted tumor cell apoptotic susceptibility in part by reducing expression of the deubiquitinase Usp9X and lead to diminished levels of anti-apoptotic Bcl-2 family members Mcl-1 and Bcl-2. In line with this, CP-d/n-ATF5-S1 synergistically enhanced tumor cell apoptosis induced by the BH3-mimetic ABT263 and the death ligand TRAIL. In vivo, CP-d/n-ATF5-S1 attenuated tumor growth as a single compound in melanoma, glioblastoma, prostate cancer and triple-receptor-negative breast cancer xenograft models. Finally, the combination treatment of CP-d/n-ATF5-S1 and ABT263 significantly reduced tumor growth in vivo more efficiently than each reagent on its own.

Conclusions: Our data support the idea that CP-d/n-ATF5-S1, administered as a single reagent or in combination with other drugs, holds promise as an innovative, safe and efficient anti-neoplastic agent against treatment-resistant cancers.
Introduction
While recent significant responses for cancer therapy have been achieved in some malignancies, these are often initially impressive, but unfortunately not durable (1,2). For other malignancies, such as high-grade primary brain cancers the prognosis is unfavorable even with treatment (3). Therefore, efforts continue to identify new potential targets for tumor-specific treatments as well as novel therapeutic strategies to exploit these targets.

ATF5 is an example that has been identified as a potential target for cancer treatment but for which no specific therapy has been developed (4,5). Activating transcription factor 5 (ATF5; also termed ATF5x), is a member of the activating transcription factor/cyclic AMP responsive element-binding (ATF/CREB) family. A common feature of this family is the presence of a basic leucine zipper (bZIP) domain that promotes DNA binding via the basic region and interactions with other proteins through the leucine zipper (5-7). ATF5 binds to several different promoter elements including the nutrient sensing report element (NRSE) and a novel motif to regulate gene transcription (6,8). Full length ATF5 appears to be rapidly degraded via the proteasome and it has the unusual property that it is among a small group of proteins that are selectively translated when eIF2α is phosphorylated (9,10).

ATF5 protein levels are increased in a variety of human malignancies, including glioblastoma, breast, pancreatic, lung and colon cancers (11). In contrast, with few exceptions (liver, prostate and testis) ATF5 expression is low in normal tissue of the respective organs. In several tumor types, including glioblastoma and non-small cell lung cancer, ATF5 expression negatively correlates with survival (12,13). In cell culture studies, ATF5 promotes survival by counteracting apoptosis in pro-B lymphocytes deprived of IL-3 or in HeLa cells after growth factor withdrawal (14). In addition, ATF5 regulates transcription of anti-apoptotic B cell leukemia 2 (Bcl-2) and of Bcl-2 family member, myeloid cell leukemia-1 (Mcl-1), presumably thereby promoting tumor cell survival (13,15). Conversely, interference with ATF5 expression or activity yields a marked induction of apoptosis in glioblastoma cells in vitro and in vivo without affecting astrocytes (16,17). Moreover, in a transgenic murine model in which endogenous glioblastomas were induced by a PDGF/sh-p53 expressing virus, activation of a dominant/negative (d/n)-ATF5 blocked tumor formation and resulted in regression of formed tumors (17). Antineoplastic activity of d/n-ATF5 was also reported for breast cancer cells and pancreatic cancer cells in vitro (11,15,18). These findings thus suggest ATF5 as a promising target for a tailored anti-cancer therapy.
To provide a potential means to target ATF5 in vivo, we designed a d/n-ATF5 linked to a cell penetrating domain (Penetratin) (19). This recombinant peptide passes the blood brain barrier, enters tumor cells and exerts antineoplastic activity in a rodent transgenic glioma model. In the present study, we assessed the activity and mechanism of action of a similar peptide (CP-d/n-ATF5-S1) that was further modified to reduce its size and that was generated synthetically. In in vitro studies and in in vivo murine xenograft models, CP-d/n-ATF5-S1 shows apoptosis induction over a broad range of recalcitrant human malignancies without apparent effects on non-transformed cells. A novel mechanism of action was found in which the peptide reduces expression of the deubiquitinating enzyme Usp9X, which in turn leads to depletion of Mcl-1 and Bcl-2 and to consequent apoptotic death. The latter findings led us to rationally design and carry out in vitro and in vivo tests of several potential combination therapies with CP-d/n-ATF5-S1 that had enhanced efficacy compared with either agent alone.

Materials and Methods

Ethics statement
All procedures were in accordance with Animal Welfare Regulations and approved by the Institutional Animal Care and Use Committee at Columbia University Medical Center.

Reagents
CP-d/n-ATF5-S1, mutated CP-d/n-ATF5-S1 and Penetratin were purchased from CS Bio (Menlo Park, CA). Recombinant TRAIL was from Peprotech (Rocky Hill, NJ). ABT263 was from Selleckchem (Houston, TX).

Cell culture
Cells were grown as described (20,21). Cells were obtained from the ATCC or Cell Line Services and authenticated by the provider. No cell line authentication was performed by the authors and details are found in the supplementary section.

Cell viability assays
To examine cellular proliferation, 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assays were performed as previously described (21).
Measurement of apoptosis and mitochondrial membrane potential
Annexin V/PI, PI and JC-1 stainings were performed as previously described (20,22).

Western blot analysis
Protein expression was determined by Western blot analysis as described before (23).

Transfections of siRNAs
siRNAs were transfected as described (22,24).

cDNA synthesis and Real-time PCR
cDNA synthesis and RT-PCR were performed as described before (23).

Subcutaneous xenograft models
Subcutaneous xenografts were implanted as previously described (20).

Statistical analysis
Statistical significance was assessed by Student’s t-test using Prism version 5.04 (GraphPad, La Jolla, CA). A p≤0.05 was considered statistically significant.
Results

CP-d/n-ATF5-S1

CP-d/n-ATF5-S1 is a synthetic 67-amino-acid peptide that was engineered to cross cellular membranes and to specifically interfere with the survival-promoting actions of ATF5 (Figure 1A). The N-terminal has a 16 amino acid Penetratin domain that facilitates cellular penetration (25,26). A dominant/negative-sequence follows in which the DNA binding domain of ATF5 is substituted by an amphipathic sequence with a leucine repeat at every seventh residue and then by the human ATF5 basic leucine zipper (bZIP) domain truncated after the first valine (26-29). Parallel work has demonstrated that a similar recombinant tagged peptide passes the blood brain barrier, enters intact cells both in vivo and in vitro and promotes selective death of glioma cells (19). Four independent batches of the peptide (including one under GMP conditions) have had comparable activity. For control purposes, peptides were also synthesized with a penetratin domain alone and in which key leucine residues were mutated to glycine in the d/n portion to reduce binding to potential partners (Figure 1A)

CP-d/n-ATF5-S1 depletes endogenous ATF5

Western blot analyses revealed that treatment of cultured tumor cell lines (T98G, MDA-MB-436 and GBM12) with CP-d/n-ATF5-S1 leads to a dose-dependent reduction of endogenous ATF5 protein levels by 3 days (Figure 1B, Suppl. fig. 1B). In T98G cells this effect was present after 48, but not 24h (Figure 1B, Suppl. fig. 1A). RNAseq analysis of T98G glioblastoma cells treated with CP-d/n-ATF5-S1 for 1-3 days showed no significant alteration of ATF5 transcript levels (data not shown). Comparison of endogenous ATF5 levels in T98G cells treated with or without CP-d/n-ATF5-S1 in presence of cycloheximide indicates that the peptide significantly decreases ATF5 protein stability (Figure 1C and 1D, Suppl. fig. 1C). In contrast, treatment with Penetratin peptide did not affect ATF5 stability (Suppl. fig. 1D and 1E). Thus, one action of CP-d/n-ATF5-S1 is loss of endogenous ATF5 caused at least in part by enhanced turnover.

CP-d/n-ATF5-S1 interferes with transcription of known ATF5 downstream targets

CP-d/n-ATF5-S1 treatment for 24h resulted in down-regulation of three known ATF5 target genes (Mcl-1 (13), Bcl-2 (15,30) and asparagine synthetase (8)) at the mRNA-level (Figure 1E, Suppl. fig. 2). However, for Mcl-1 and Bcl-2, this decrease was transitory with mRNA levels returning to baseline by 72h, presumably by compensatory mechanisms. In contrast, CP-d/n-ATF5-S1 did not decrease mRNA levels of Usp9X, a gene not described as transcriptionally regulated by ATF5 (Figure 1E).
CP-d/n-ATF5-S1 promotes apoptotic cell death across a wide panel of treatment-resistant human cancer cell lines

ATF5 is expressed in a variety of human cancers including glioblastoma (11,15,18). *In silico* analysis of the Rembrandt data set for glioblastoma shows a significantly worse overall survival in patients harboring an amplification of the ATF5 gene compared with those with ≤ 1.8 copies (Figure 1F). Several studies have also reported an inverse relationship between ATF5 protein expression and GBM patient survival (5).

Inhibition of ATF5 function or expression has marked anti-neoplastic effects *in vitro* and *in vivo* (11,15,16,18). Initially, to assess the activity of CP-d/n-ATF5-S1, T98G, U87MG glioblastoma and HL-60 myeloid leukemia cells were treated for 72h with increasing concentrations of the peptide. CP-d/n-ATF5-S1 yielded a dose-dependent anti-proliferative effect as determined by MTT assay (Figure 1G and Suppl. fig. 3) as well as marked changes in cellular morphology observed by light microscopy (Figure 1H). To further assess the mechanism of such effects, we performed annexin V/PI staining across a variety of therapy-refractory human cancer cell lines after treatment with increasing concentrations of CP-d/n-ATF5-S1 for 48h. As shown in Figure 2A-C, Suppl. fig. 4A and 4C and Suppl. fig. 5A, the peptide yielded a strong and dose-dependent increase in the fraction of annexin V-positive cells, thus indicating an apoptotic response across a wide and diverse panel of solid and non-solid cancer cells. Moreover, this effect was attenuated by treatment with the pan-caspase inhibitor z-VAD-Fmk in T98G cells (Suppl. fig. 6), which is consistent with studies indicating that interference with ATF5 function or expression in tumor cells promotes apoptosis (9,12).

To verify whether the effect of the peptide on survival is specifically related to the dominant-negative domain and not to the cell-penetrating domain, we treated T98G cells either with Penetratin alone or CP-d/n-ATF5-S1. In contrast to CP-d/n-ATF5-S1, Penetratin did not markedly increase the fraction of annexin V-positive cells (Figure 2D and E). Moreover, neither Penetratin nor CP-d/n-ATF5-S1 resulted in a significant induction of apoptosis in human fetal astrocyte cultures (Figure 1F and G), suggesting that CP-d/n-ATF5-S1 possesses specificity towards cancer cells.
CP-d/n-ATF5-S1 leads to dissipation of mitochondrial membrane potential and activates caspase-9

Next, we addressed whether activation of apoptosis by CP-d/n-ATF5-S1 is mediated at least in part through a mitochondrial pathway. JC1 staining revealed that peptide treatment leads to a marked reduction of mitochondrial membrane potential (Figure 2H) and cleavage (activation) of caspase-9, suggesting that CP-d/n-ATF5-S1 induces apoptosis in part through the mitochondrially-driven apoptotic pathway (Figure 2I).

CP-d/n-ATF5-S1 down-regulates anti-apoptotic Bcl-2 and Mcl-1 proteins

Because our findings pointed towards involvement of mitochondria in apoptosis driven by CP-d/n-ATF5-S1, we next focused on expression of Bcl-2 family proteins. ATF5 is reported to suppress transcription of anti-apoptotic Bcl-2 and Mcl-1 (13,30). However, at least in T98G cells, there was a rebound of Mcl-1 and Bcl-2 mRNA expression by 3 days of peptide treatment (Figure 1E), so it was important to assess protein levels at this time as well. As shown in Figure 3A and Suppl. fig. 7A, Mcl-1 was consistently down-regulated in all lines tested (U87MG, T98G glioblastoma and H1975 non-small cell lung cancer, PANC-1 pancreatic carcinoma, A375 melanoma and PC3 prostate cancer) at 72h of peptide treatment and in some cases, by 48h. Bcl-2 protein was similarly down-regulated in all but the PC3 cell line. Expression of Bcl-xL, a third member of the anti-apoptotic Bcl-2 family, was altered in some lines (U87MG and T98G), but not in others. Despite a rebound of Mcl-1 and Bcl-2 mRNA levels in T98G cells by 3 days of CP-d/n-ATF5-S1 treatment, expression of the corresponding protein was still decreased in these cells after 6 days of peptide treatment (Suppl. fig. 1F).

CP-d/n-ATF5-S1 down regulates Bag3 and Usp9X proteins

The observed decreases in Mcl-1 and Bcl-2 proteins at 72h promoted by CP-d/n-ATF5-S1 under conditions in which mRNA levels appear to be unaffected led us to next assess whether the peptide affects expression of Bcl-2 family members by a post-transcriptional mechanism. For instance, Mcl-1 is stabilized by its chaperone Bcl-2-associated athanogene 3 (Bag3) on one hand and by deubiquitination through the ubiquitin-specific peptidase 9, X-linked (Usp9X) on the other (31,32). Therefore, we determined protein levels of Bag3 and Usp9X in a panel of tumor lines following treatment with increasing concentrations of CP-d/n-ATF5-S1 for 48-72h. Usp9X expression was greatly reduced by peptide treatment in a time- and dose-dependent manner, while Bag3 levels fell particularly in U87MG, T98G and PC3 cells (Figure 3A, Suppl. fig. 7A and 7B). CP-d/n-ATF5-S1-mediated reduction in Usp9X protein levels was not rescued by z-VAD-
fmk, indicating that Usp9X depletion is most likely independent of apoptosis and activated caspases as well as of its mRNA levels (Suppl. fig. 8 and Figure 1E).

**Usp9X knockdown induces apoptosis, caspase activation and recapitulates effects of CP-d/n-ATF5-S1**

The consistent effect of CP-d/n-ATF5-S1 on Usp9X expression led us to examine whether silencing Usp9X by another means would be sufficient to phenocopy the pro-apoptotic effect of the peptide. Similarly to cells treated with CP-d/n-ATF5-S1, T98G, U251 and LN229 glioblastoma cells in which Usp9X was silenced with siRNA showed marked reduction in viability as indicated by annexin V/PI or propidium iodide staining (Figure 3B, Suppl. fig. 9A). This was accompanied by a substantial increase in cleavage of caspases-9 and -3 (Figure 3C, Suppl. fig. 9B). Additionally, there was significant reduction in Bag3, Mcl-1 and Bcl-2 protein expression in both U251 and T98G cells. Taken together these findings indicate that loss of Usp9X expression promoted by CP-d/n-ATF5-S1 treatment is sufficient to diminish levels of key anti-apoptotic Bcl-2 family members and to induce cell death.

**CP-d/n-ATF5-S1 sensitizes for apoptosis induced by BH3-mimetics**

Mcl-1 is a major resistance factor towards BH3-mimetics such as ABT737/263/199, and a considerable number of solid malignant tumors, including gliomas, bear high levels of Mcl-1 (33,34). Given that CP-d/n-ATF5-S1 modulates anti-apoptotic members of the Bcl-2 family, especially Mcl-1 and its interacting proteins, we examined whether the peptide may act in a complementary or synergistic fashion with BH3-mimetic agents. We accordingly treated T98G cells with CP-d/n-ATF5-S1 and Bcl-2/Bcl-xL inhibitor ABT263 or the Bcl-2/Bcl-xL/Mcl-1 inhibitor GX15-070. In both instances, combined treatment caused synergistic inhibition of cell viability as assessed by MTT assay (Figure 4A, Suppl. fig. 10A). In concordance, cellular morphology was markedly changed in cells subjected to the combination treatments and pointed, as anticipated, towards apoptosis as the underlying mechanism. (Figure 4B). Because GX15-070 has activities in addition to Bcl-2 family inhibition (35), we focused further combinatorial studies on ABT263. Enhancement of ABT263-mediated apoptosis by CP-d/n-ATF5-S1 was confirmed by annexin V/PI staining. The combination treatment significantly up-regulated the fraction of annexin V-positive cells in T98G, LN229, SF188 (pediatric), NCH644 (glioma stem-like) and GBM12 glioblastoma cultures as well as in PANC-1 pancreatic carcinoma, A375 melanoma, K562 chronic myeloid leukemia (in blast crisis) and HCT116 colorectal cancer cell cultures (Figure 4C and E, Suppl. fig. 5B and Suppl. fig. 11). Consistent with these findings, combined
treatment with CP-d/n-ATF5-S1 and ABT263 also enhanced caspase-9 cleavage in T98G cells (Figure 4F).

In the context of these experiments, we also assessed a Penetratin-only peptide and a form of CP-d/n-ATF5-S1 mutated in the extended leucine zipper (Figure 1A) to diminish its interaction with other proteins. In comparison with CP-d/n-ATF5-S1, the mutated peptide showed markedly less effect on T98G cell morphology either alone or in combination with ABT263 (Figure 4B). The mutated peptide also showed much less effect on apoptosis when applied alone and minimally enhanced apoptosis when combined with the BH3-mimetic (Figure 4D). Moreover, combined treatment with the Penetratin peptide and ABT263 resulted in an antagonistic antiproliferative effect (Suppl. fig. 10B).

**Combined CP-d/n-ATF5-S1 and ABT263 treatment promotes enhanced down-regulation of Mcl-1 and Bcl-2 which in turn results in enhanced apoptotic death**

We next examined the effect of combined treatment with CP-d/n-ATF5-S1 and ABT263 on expression of anti-apoptotic Bcl-2 family members. As illustrated in Figure 4F, ABT263 alone increased expression of Mcl-1 – a finding that represents a generally accepted mechanism of resistance to BH3-mimetic compounds (34). However when ABT263 was combined with CP-d/n-ATF5-S1, Mcl-1 expression was highly suppressed, as was expression of Bcl-2 and Bcl-xL (Figure 4F). In contrast, combined treatment with ABT263 and mutated CP-d/n-ATF5-S1 yielded only a slight decrease in Mcl-1 and Bcl-2 expression (Figure 4F).

Part of the rationale for combining CP-d/n-ATF5-S1 with ABT263 is that unlike the latter, the former promotes Mcl-1 down-regulation. To examine whether down-regulation of Mcl-1, as occurs with CP-d/n-ATF5-S1, is sufficient to sensitize for ABT263-mediated apoptosis, we silenced Mcl-1 in PANC-1 cells with siRNA prior to treatment with ABT263 (Suppl. fig. 12A). Mcl-1 knock-down combined with ABT263 yielded markedly enhanced cleavage of caspases-9 and -3. Additionally, Bag3, Usp9X and Bcl-2 expression was significantly reduced under these conditions compared with cells either silenced for Mcl-1 and/or treated with ABT263 alone. These observations were also reflected by an enhanced reduction in the fraction of viable LN229 cells remaining after silencing Mcl-1 and treating with ABT263, as compared to treating with either alone (Suppl. fig. 12B). Similarly, when Usp9X was silenced, LN229 cells became more susceptible to the cytotoxic effects of ABT263 (Suppl. fig. 12C).
Thus, when combined with ABT263, specific knock-down of Mcl-1 and Usp9X (as seen after treatment with CP-d/n-ATF5-S1) suffices to reproduce the molecular profile of combined treatment with CP-d/n-ATF5-S1 and ABT263.

**CP-d/n-ATF5-S1 enhances apoptosis induced by the death receptor ligand TRAIL**

Next, we examined whether combined treatment with CP-d/n-ATF5-S1 also enhances apoptosis triggered by the extrinsic pathway. Our reasoning was that if the peptide increases sensitivity to the mitochondrial apoptotic pathway, it might complement or enhance mitochondrial-dependent and/or -independent apoptotic actions of a death-promoting ligand. We therefore treated T98G cells with CP-d/n-ATF5-S1 and increasing concentrations of TNF-related apoptosis-inducing ligand (TRAIL). As shown in Figure 5A, treatment with this combination results in an enhanced anti-proliferative effect in the MTT assay compared to control or single treatments. In contrast, the combination of TRAIL with mutated CP-d/n-ATF5-S1 did not show this effect. Representative microphotographs in Figure 5B illustrate these findings at the level of morphology. Annexin V/PI staining also showed that CP-d/n-ATF5-S1 enhances TRAIL-mediated apoptosis in T98G cells as well as in LN229 glioblastoma cells and MDA-MB-436 breast cancer cells (Figure 5C and E). In this assay, mutated CP-d/n-ATF5-S1 alone only slightly increased apoptotic cells when compared to controls and did not enhance TRAIL-induced apoptosis (Figure 5D). In concordance with these findings, the combination therapy led to reduced expression of full length caspase-3 in T98G cells, presumably due to elevated cleavage of this protein (Figure 5F). Mutated CP-d/n-ATF5-S1 did not have this effect. In addition, combined treatment with CP-d/n-ATF5-S1 and TRAIL enhanced down-regulation of Mcl-1 and Bcl-2 expression (Figure 5F). Treatment with TRAIL alone in this cell line reduced expression of Bcl-xL, though this effect was neither matched nor enhanced by CP-d/n-ATF5-S1 (Figure 5F).

**CP-d/n-ATF5-S1 sensitizes for TRAIL-mediated apoptosis at least in part by down-regulating Bag3 and Mcl-1**

Decreased expression of Mcl-1 following treatment with CP-d/n-ATF5-S1 represents a mechanism likely to contribute to the CP-d/n-ATF5-S1-mediated sensitization towards TRAIL. Because Bag3 stabilizes Mcl-1 (23) and our data indicate that CP-d/n-ATF5-S1 down-regulates Bag3 in most cell lines tested (Figure 5G), we examined whether Bag3 knock-down would phenocopy the sensitizing effect of CP-d/n-ATF5-S1 towards TRAIL. Silencing Bag3 in LN229 glioblastoma cells results in down-regulation of Mcl-1 (Figure 5G). When combined with TRAIL,
Bag3 knock-down markedly increased cleavage of caspases-9 and -3. Consistent with these observations, treatment with Bag3-siRNA and TRAIL yields a significant increase in apoptosis of LN229 cells as determined by annexin V/PI staining (Figure 5H). Moreover, TRAIL combined with silencing of Mcl-1 with siRNA also markedly increased cleavage of caspases-9 and -3 and apoptosis in LN229 cells (Figure 5I and J). In contrast, Bag3 and Usp9X levels were not affected by Mcl-1 knock-down alone or when combined with TRAIL (Figure 5I). Taken together, these findings indicate that CP-d/n-ATF5-S1 sensitizes tumor cells to TRAIL and that this occurs at least in part by loss of Mcl-1 due to reduction of Bag3 expression.

**CP-d/n-ATF5-S1 significantly attenuates tumor growth in vivo**

We next assessed the therapeutic efficacy of CP-d/n-ATF5-S1 in multiple murine xenograft models. U87MG glioblastoma, A375 melanoma, PC3 prostate cancer cells, PANC-1 pancreatic cancer cells and HCT116 colorectal cancer cells were implanted subcutaneously; MDA-MB-231 triple-negative breast cancer cells were implanted in the mammary fat pad; and GBM12 patient-derived xenografts were implanted intracranially. Once tumors formed, mice were randomized and treated with CP-d/n-ATF5-S1, vehicle or penetratin peptide as outlined in Figure 6A-C, Suppl. fig. 5C, Suppl. fig. 13 and Suppl. fig. 14. Under these conditions, except for the cases of PANC-1 cells (p=0.25) and HCT116 cells (p=0.18), in all tumor types animals that received treatment with CP-d/n-ATF5-S1 had significantly smaller tumors than the animals treated with vehicle or Penetratin (Figure 6B,C; Suppl. fig. 5C, Suppl. fig. 13 and Suppl. fig. 14). Moreover, in a GBM12 intracranial patient-derived xenograft model, animals treated with CP-d/n-ATF5-S1 showed a median survival of 38 days which was significantly prolonged compared to 22.5 days in animals receiving vehicle (Figure 6A). While the treatments used here affected tumor growth rate, for the most part, they did not result in statistically significant regression of tumors. However, there was a statistically significant tumor regression in mice bearing MDA-MB-231 breast cancer mammary fat pad xenografts (Suppl. fig. 14E-G). This effect was not observed when mice were treated with Penetratin alone (Suppl. fig. 14E-G).

To detect possible toxic effects due to peptide treatment, histological analysis was performed on various tumor-free tissues of animals treated with either vehicle or CP-d/n-ATF5-S1 according to the dosing schedule described in Figure 6C. No tissue alterations in brain, lung, kidney, heart, liver, spleen, and intestine were found (Suppl. fig. 15A). Moreover, the body weights of the animals did not vary between the treatment groups toward the end of the experiment (Suppl. fig. 15B).
Combined treatment with CP-d/n-ATF5-S1 and ABT263 significantly enhances attenuation of tumor growth in vivo

Our in vitro studies indicated that combined CP-d/n-ATF5-S1 and ABT263 treatment enhanced tumor cell death due to additive and complementary effects on anti-apoptotic Bcl-2 family members. To assess whether the combination is more effective in vivo than either treatment alone, we utilized a U251 heterotopic glioblastoma xenograft model and a HCT116 heterotopic colorectal cancer xenograft model Figure 6D and Suppl. fig. 5C. The mice with xenografted tumors were divided into four groups: vehicle, ABT263, CP-d/n-ATF5-S1 or the combination of ABT263 and CP-d/n-ATF5-S1. As shown in Figure 6D, in the U251 model, at the end point of the study, animals that received the combination treatment had significantly smaller tumors compared to those treated either with ABT263 or CP-d/n-ATF5-S1 alone and showed a decrease in tumor size over time when compared to the beginning of treatment. Similarly, in the HCT116 model the combination treatment led to significant reduction in tumor growth rate when compared to vehicle or single-agent treatments (Suppl. fig. 5C). The combination treatment also showed no clinical signs of toxicity, indicating that although the combined treatment is more efficient, it does not increase the occurrence of evident side effects.

Discussion

Cancer cells typically develop primary or secondary resistance to apoptosis (36). Therefore, means to manipulate the apoptotic machinery are pivotal to restore therapeutic sensitivity. Deregulation of the apoptotic machinery is mediated through numerous factors, such as the Bcl-2 family of proteins, the Inhibitor of Apoptosis Proteins and expression of death receptors, initiator caspases and endogenous caspase inhibitors (37,38). The aberrant expression of such molecules is regulated by various means, including the actions of transcription factors. ATF5 is an example of a transcription factor with oncogenic potential that affects Bcl-2 family member expression (13,16). ATF5 is up-regulated in various malignancies, including highly prevalent tumors, such as breast carcinoma (11), but it is also increased in less common malignancies, such as low- and high-grade gliomas (13,16). In the context of low- and high-grade gliomas, ATF5 expression levels are not only increased, but also correlate with survival (13). Thus, ATF5 represents a potential target in treatment refractory cancers.

Here, we show that a novel synthetic cell penetrating dominant-negative ATF5 peptide induces apoptosis in a broad range of tumor types, including glioblastoma, triple-negative breast cancer (MDA-MB-436), hormone-refractory prostate cancer (PC3 and DU145), EGFR kinase inhibitor
resistant non-small cell lung cancer (H1975), BRAF (V600E)-mutated melanoma (A375) and pancreatic carcinoma (PANC-1). CP-d/n-ATF5-S1 also showed in vivo efficacy in reducing growth of a range of tumor types in xenograft models. We have yet to optimize dosing or regimens of administration. Our in vitro and in vivo studies indicate that the peptide does not kill non-transformed cells and causes no evident histological or behavioral signs of toxicity in mice at levels up to at least 150 mg/kg. With respect to specificity, a Penetratin peptide and a peptide in which key leucine residues in CP-d/n-ATF5-S1 were mutated showed no or little apoptotic activity alone or in combination studies. The fact that ATF5, as a pro-survival factor is overexpressed in cancer cells, may cause a state of cellular ATF5-dependency in the sense of oncogene addiction. This would explain the selective response towards CP-d/n-ATF5-S1 treatment in cancer cells as a consequence of a sudden CP-d/n-ATF5-S1-mediated loss of ATF5 function.

CP-d/n-ATF5-S1-mediated cell death was accompanied by depletion of endogenous ATF5 protein suggesting that CP-d/n-ATF5-S1 may induce cell death in part through depletion of total ATF5 levels. In that context, earlier results showed that depletion of ATF5 by siRNA/shRNA leads to cell death in a broad variety of tumor cells (11,13,15). It remains to be determined by what underlying mechanisms CP-d/n-ATF5-S1 controls ATF5 protein levels. Our observations suggest that this is a non-transcriptional event. Given that ATF5 possesses a short-half life (39) and is stabilized by chaperones (39), it is conceivable that CP-d/n-ATF5-S1 enhances ATF5’s degradation through disruption of its interactions with other binding partners.

Consistent with its activation of the intrinsic apoptotic pathway, CP-d/n-ATF5-S1 modulated the expression of the anti-apoptotic Bcl-2 protein family, including Mcl-1, Bcl-2 and, in some instances, Bcl-xL. Particularly at earlier time points, there is an occasional CP-d/n-ATF5-mediated increase in Bcl-xL, which, however, for most cell lines (except for PANC1) tested is not sustained. Additional research will shed light on why CP-d/n-ATF5-S1 causes this biphasic modulation of Bcl-xL. Nevertheless, one possible consequence might be that the increase in Bcl-xL might render tumor cells more sensitive to Bcl-xL inhibitors, such as ABT263. These are known to counteract Bax-dependent apoptosis by preventing mitochondrial outer membrane permeabilization and subsequent cytochrome-c release and caspase-9 activation.

Although Bcl-2 and Mcl-1 have been described as transcriptional targets of ATF5, our findings indicate that CP-d/n-ATF5-S1 causes only a transient decrease in their transcript levels and that
Mcl-1, in particular, is subject to sustained down-regulation at the posttranscriptional level by CP-d/n-ATF5-S1. Several molecules have been described that control Mcl-1 levels posttranslationally. Examples include MULE (40), Bag3 (31) and Usp9X (32). Bag3 is a co-chaperone of Hsp70 (41) and binds Mcl-1 to prevent its degradation, while Usp9X is a deubiquitinase that removes ubiquitin chains from Mcl-1, rendering it resistant to proteasomal degradation and thereby in turn increasing its half-life (32). Both Bag3 and Usp9X have been shown to counteract intrinsic apoptosis. For instance, Bag3 is up-regulated in malignant gliomas and intereferes with Bax-mediated apoptosis (42) while Usp9X knockdown enhances ABT263-mediated cell death in glioblastoma (20,33). Usp9X interacts with a variety of molecules in addition to Bcl-2 proteins that may also affect cell survival (43,44) and these too may thus play a role in tumor cell death promoted by CP-d/n-ATF5-S1.

Our findings show that in PC3, PANC-1, T98G, H1975, A375 and U87MG cells, CP-d/n-ATF5-S1 significantly affects protein levels of Usp9X starting as early as 48h and continuing at 72h after treatment, when apoptotic death is manifest. To assess the impact of Usp9X depletion by CP-d/n-ATF5-S1, we transfected glioblastoma cells with Usp9X siRNA and found that this was sufficient to induce significant apoptotic death. Mechanistically, Usp9X knockdown caused concomitant suppression of Bag3, Mcl-1 and Bcl-2 expression, which remarkably recapitulates the effects of CP-d/n-ATF5-S1 on these molecules. These observations suggest that CP-d/n-ATF5-S1-mediated suppression of Usp9X levels may be an instrumental mechanism by which it mediates death of neoplastic cells. While Usp9X is known to modulate Mcl-1 expression, our observed effects of Usp9X manipulation on Bag3 and Bcl-2 have not been previously described and may suggest that Usp9X also interacts with Bag3 as well as Bcl-2. The mechanism(s) by which CP-d/n-ATF5-S1 decreases Usp9X expression remain to be explored. Our data indicate a post-transcriptional mechanism in that the peptide does not affect Usp9X mRNA levels. The strong antineoplastic activity related to Usp9X down-regulation warrants further studies directed at identification of specific small-molecule inhibitors of Usp9X function.

Given our observation that CP-d/n-ATF5-S1 strongly affects the intrinsic apoptotic machinery and the possibility that treatment with a single drug may fall short in the clinic, we investigated whether rational drug combination therapies could enhance the efficacy of CP-d/n-ATF5-S1. For that purpose, we utilized the orally available BH3-mimetic ABT263 (43). This class of compounds has received great attention since they target both Bcl-2 and Bcl-xL, which are up-regulated in many malignancies, especially in hematological malignancies, such as follicular
lymphoma (45), and also in solid neoplasms, such as glioblastoma (46). While certain tumors demonstrate remarkable sensitivity for BH3-mimetics, others reveal resistance, which in the vast majority of cases is attributed to high-levels of Mcl-1 expression (47). Therefore, means to counteract high Mcl-1 protein levels may sensitize resistant tumors to BH3-mimetic treatment (48,49). In the current case, we found that CP-d/n-ATF5-S1 strongly depresses expression of two Mcl-1 interacting proteins, Bag3 and Usp9X, and that this in turn leads to Mcl-1 depletion. These considerations led us to assess the combination of CP-d/n-ATF5-S1 and ABT263 in vitro and in vivo xenograft tumor models. We found enhanced cell death by this combination in a variety of tumor cell lines, including LN229 and A375 that are relatively resistant to ABT263. In the in vivo models, the combination was highly effective compared with the single treatments and blocked/reduced tumor growth over the course of the studies.

Because the Bcl-2 family is also implicated in extrinsic apoptosis, we tested whether CP-d/n-ATF5-S1 overcomes resistance to TRAIL. TRAIL has received attention for its ability to kill a broad variety of cancer cells in vitro and in vivo. One main obstacle for TRAIL-related therapies is that while a subset of tumors respond, the majority display resistance (50). Therefore, efforts have aimed to identify treatments that sensitize cancer cells to TRAIL therapeutics. Our results suggest that CP-d/n-ATF5-S1 is a potent sensitizer for TRAIL-mediated apoptosis. Mechanistically this is most likely linked to the ability of CP-d/n-ATF5-S1 to suppress Bag3 and Mcl-1, since specific knockdown of Bag3 or Mcl-1 was sufficient to sensitize TRAIL-resistant LN229 glioblastoma cells to apoptosis.

Overall, our results serve as a proof of principle and suggest that the strategy of treatment with a cell penetrating dominant-negative form of ATF5 is efficacious, selective and non-toxic and therefore holds promise for cancer therapy, either alone or in a multi-targeting approach.

Acknowledgements
We thank Yanping Sun for excellent assistance with the MRI studies.
References


11. Monaco SE, Angelastro JM, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer 2007;120(9):1883-90.


Figure legends:

**Figure 1:**

A, Graphical representation showing the sequences of CP-d/n-ATF5-S1, Mutated CP-d/n-ATF5-S1 and Penetratin. B, T98G glioblastoma and MDA-MB-436 breast cancer cells were treated for 72h with increasing concentrations of CP-d/n-ATF5-S1 under reduced serum conditions to mimic the nutrient-deprived state of tumor cells in the tumor tissue (1.5% FBS) followed by Western blot analysis for ATF5. Actin Western blot analysis was performed to confirm equal protein loading. Arrow indicates the specific band of ATF5. C, T98G glioblastoma cells were treated with CP-d/n-ATF5-S1 or solvent for 48h prior to adding 10 μM cycloheximide and Western blot analysis for ATF5 and actin. D, Graphical representation following densitometric analysis of the experiment described under C using ImageJ (National Institutes of Health, U.S.A., [http://imagej.nih.gov/ij](http://imagej.nih.gov/ij)). E, T98G glioblastoma cells were treated for the indicated durations with 100 μM Penetratin (pen) or increasing concentrations of CP-d/n-ATF5-S1 prior to performing rtqPCR for Mcl-1, Bcl-2 and Usp9X. Columns: Mean. Error bars: standard deviation. * signifies a p-value of less than 0.05 versus treatment with pen for 24h. # signifies a p-value of less than 0.05 versus treatment with pen for 72h. F, In silico analysis on the survival of glioblastoma patients based on the amplification status of the ATF5 gene (National Cancer Institute. 2005. REMBRANDT home page. <http://rembrandt.nci.nih.gov>). Accessed 2014 August 24). G, T98G glioblastoma cells were treated with increasing concentrations of CP-d/n-ATF5-S1 under low serum conditions (1.5% FBS). After 72h, a MTT assay was performed. Data presented are representative for at least two independent experiments. Columns: means. Error bars: standard error of the mean (SEM). H, representative microphotographs of U87MG cells at 40x magnification after 72h of treatment with CP-d/n-ATF5-S1. Morphological changes such as decreased lengths and numbers of cell processes are especially seen in those cells treated with 200 μM CP-d/n-ATF5-S1. Black arrow tip points at blebs.

**Figure 2:**

A, U87MG, T98G, U251, LN229, MGPP-3 (transgenic, proneural) glioblastoma, PC3 and DU1145 prostate cancer, PANC-1 pancreatic carcinoma, MDA-MB-436 triple negative breast cancer, H1975 non-small cell lung cancer, A375 malignant melanoma HL-60 myeloid leukemia, SU-DHL4 diffuse large B-cell lymphoma, K562 chronic myeloid leukemia (in blast crisis) and Raji Burkitt lymphoma cells were treated for 48h with increasing concentrations of CP-d/n-ATF5-S1 prior to staining with annexin V/propidium iodide and flowcytometric analysis. Quantitative representation of the fraction of viable cells (annexin V and PI-negative cells). Columns, means
of three serial measurements. Bars, SD. B and C, Representative flow plots of cells treated as described for A. Lower left quadrant, fraction of viable cells; upper left quadrant, fraction of necrotic cells; lower right quadrant, fraction of early apoptotic cells and upper right quadrant, fraction of late apoptotic cells. D, T98G glioblastoma cells were treated for 48h either with Penetratin or CP-d/n-ATF5-S1. Then staining for annexin V/PI was performed to detect apoptosis. E, Quantitative representation of cells treated as described for D. Columns, means of three serial measurements. Bars, SD. F, Human astrocytes were treated for 48h either with Penetratin or CP-d/n-ATF5-S1 and then staining for annexin V/PI was performed to detect apoptosis. G, Quantitative representation of cells treated as described for D. Columns, means of three serial measurements. Bars, SD. H, Representative flow plots of T98G glioblastoma cells that were treated for 48h with indicated concentrations of CP-d/n-ATF5-S1 prior to staining with JC-1 and flow cytometric analysis. I, T98G glioblastoma cells were treated for 6h with CP-d/n-ATF5-S1 or control. Whole cell extracts were collected and Western blot for caspase-9 (CP9) and actin was performed. The cleaved form of caspase-9 is marked by CF.

**Figure 3:**
A, U87MG and T98 glioblastoma as well as H1975 non-small cell lung cancer and PANC-1 pancreatic cancer cells were treated with increasing concentrations of CP-d/n-ATF5-S1 for 48h and 72h under reduced serum conditions. Whole-cell extracts were examined by Western blot for Mcl-1, Bcl-2, Bcl-xL, Usp9X and Bag3. Actin Western blot analysis was performed to confirm equal protein loading. pen indicates the usage of 100 µM Penetratin as control. Densitometric analysis was performed using ImageJ (National Institutes of Health, U.S.A., [http://imagej.nih.gov/ij](http://imagej.nih.gov/ij)). B, T98G, U251 and LN229 glioblastoma cells were treated with non-targeting (n.t.)-siRNA or Usp9X-siRNA prior to staining with PI or annexin V/PI and flow cytometric analysis. C, T98G and U251 glioblastoma cells were treated with non-targeting (n.t.)-siRNA or Usp9X-siRNA followed by Western blot analysis for Usp9X, Bag3, Mcl-1, Bcl-2, Bcl-xL and in U251 glioblastoma cells in addition for cleaved caspase-3 (cCP3) and caspase-9 (CP9). Actin Western blot analysis was performed to confirm equal protein loading. Densitometric analysis was performed using ImageJ (National Institutes of Health, U.S.A., [http://imagej.nih.gov/ij](http://imagej.nih.gov/ij)).

**Figure 4:**
A, T98G glioblastoma cells were treated for 72h under reduced serum conditions (1.5% FBS) with CP-d/n-ATF5-S1 (100 µM), ABT263 (0.5 µM) or GX15-070 (50 nM) at the indicated
combinations prior to performing MTT assays. Columns: means. Error bars: standard deviation (SD). B, Representative microphotographs at 20x magnification of T98G glioblastoma cells treated with CP-d/n-ATF5-S1, ABT263, the combination of both or solvent for 48h. In addition, microphotographs of cells treated with mutated CP-d/n-ATF5-S1 alone or combined with ABT263 (0.5 µM) are shown. C, Representative flow plots of T98G, LN229, SF188 (pediatric), NCH644 (glioma stem-like) glioblastoma and PANC-1 pancreatic carcinoma, A375 melanoma, K562 chronic myeloid leukemia (in blast crisis) cells that were treated for 72h with CP-d/n-ATF5-S1 (100 µM), ABT263 (0.5 µM), the combination of both or solvent prior to staining with annexin V/propidium iodide and flowcytometric analysis. D, Representative flow plots of T98G glioblastoma cells subjected to treatment with mutated CP-d/n-ATF5-S1 alone or in combination with ABT263. E, Quantitative representation of the fraction of annexin V and/or PI-positive cells treated as described for C. * signifies a p-value of less than 0.05. Columns, means of three serial measurements. Bars, SD. F, T98G glioblastoma cells were treated with CP-d/n-ATF5-S1 (100 µM), mutated CP-d/n-ATF5-S1 (100 µM) and ABT263 (0.5 µM) at indicated combinations for 48h under serum starvation. Whole-cell extracts were examined by Western blot for caspase-9 (CP9, CF=cleaved fragment), Mcl-1, Bcl-2 and Bcl-xL. Actin Western blot analysis was performed to confirm equal protein loading. Densitometric analysis was performed using ImageJ (National Institutes of Health, U.S.A., http://imagej.nih.gov/ij). Data were normalized first to the respective actin control and second to the respective treatment control.

Figure 5:
A, T98G glioblastoma cells were treated with CP-d/n-ATF5-S1 (50 µM), mutated CP-d/n-ATF5-S1 (50 µM) and increasing concentrations of TRAIL as indicated. After 72h MTT assays were performed. Columns: means. Error bars: standard deviation (SD). B, representative microphotographs at 40x magnification of T98G glioblastoma cells treated with CP-d/n-ATF5-S1, TRAIL, the combination of both or solvent for 48h. In addition, microphotographs of cells treated with mutated CP-d/n-ATF5-S1 (100 µM) alone or combined with TRAIL (5 ng/ml) are shown. C, Representative flow plots of T98G, LN229 glioblastoma and MDA-MB-436 breast cancer cells treated for 72h with CP-d/n-ATF5-S1, TRAIL, the combination of both or solvent at the indicated concentrations prior to staining with annexin V/propidium iodide and flowcytometric analysis. D, Representative flow plots of T98G glioblastoma cells subjected to treatment with mutated CP-d/n-ATF5-S1 alone or in combination with TRAIL prior to staining for annexin V/PI and flowcytometric analysis. E, quantitative representation of the fraction of annexin V and/or PI-positive cells for T98G, LN229 and MDA-MB-436 cells that were treated as in C. Columns,
means of three serial measurements. Bars, SD. F, T98G glioblastoma cells were treated with CP-d/n-ATF5-S1 (100 μM), mutated CP-d/n-ATF5-S1 (100 μM) and TRAIL (5 ng/ml) at indicated combinations for 24h under reduced serum conditions. Whole-cell extracts were examined by Western blot for caspase-3 (CP3), Mcl-1, Bcl-2 and Bcl-xL. Actin Western blot analysis was performed to confirm equal protein loading. Densitometric analysis was performed using ImageJ (National Institutes of Health, U.S.A., http://imagej.nih.gov/ij). Data were normalized first to the respective actin control and second to the respective treatment control. G, LN229 glioblastoma cells were treated with non-targeting (n.t.)-siRNA, Bag3-siRNA and TRAIL as indicated. Whole-cell extracts were examined by Western blot for caspase-9 (CP9, CF=cleaved fragment), cleaved caspase-3 (cCP3), Usp9X, Bag3, Mcl-1, Bcl-2 and Bcl-xL. Actin served as loading control. H, Representative flow plots of LN229 glioblastoma cells treated with non-targeting (n.t.)-siRNA or Bag3-siRNA prior to additional treatment with TRAIL or solvent for 24h and staining with annexin V/propidium iodide plus flowcytometric analysis. I, LN229 glioblastoma cells were treated with non-targeting (n.t.)-siRNA, Mcl-1-siRNA and TRAIL as indicated. Whole-cell extracts were examined by Western blot for caspase-9 (CP9, CF=cleaved fragment), cleaved caspase-3 (cCP3), Usp9X, Bag3, Mcl-1, Bcl-2 and Bcl-xL. Actin served as loading control. J, Representative flow plots of LN229 glioblastoma cells treated with non-targeting (n.t.)-siRNA or Mcl-1-siRNA prior to additional treatment with TRAIL or solvent for 24h and staining with annexin V/propidium iodide plus flowcytometric analysis.

Figure 6:
A, 3x10^5 GBM12 glioblastoma cells were implanted intracranially. After tumor formation animals were treated intraperitoneally with vehicle (n=6) or CP-d/n-ATF5-S1 (n=7). Treatment was started on day 5 with a dose escalation from 50 to 150mg/kg over the first 4 days followed by a de-escalation to a maintenance therapy of 75mg/kg, 3x/week. Microphotographs at 2x and 40x magnification of a representative tumor from the vehicle-treated group are shown as well as representative brain MRIs of animals treated with vehicle or CP-d/n-ATF5-S1. B, 1x10^6 A375 malignant melanoma cells were implanted subcutaneously. After tumor formation animals were treated intraperitoneally with vehicle (n=12 tumors) or CP-d/n-ATF5-S1 (n=12 tumors) as indicated. C, 1x10^6 PC3 prostate cancer cells were implanted subcutaneously. After tumor formation animals were treated intraperitoneally with vehicle (n=12 tumors) or CP-d/n-ATF5-S1 (n=12 tumors) as indicated. D, 1x10^6 U251 glioblastoma cells were implanted subcutaneously. After tumor formation animals were treated intraperitoneally with vehicle (n=9 tumors), CP-d/n-ATF5-S1 (n=9 tumors), ABT263 (n=9 tumors) or the combination of CP-d/n-ATF5-S1 and
ABT263 (n=9 tumors) as indicated. Data are presented as mean and SEM. The student’s t-test was used for statistical analysis and a p-value of less than 0.05 was considered statistically significant. Representative photographs of the tumors are provided.
Figure 1

A

CP-d/n-ATF5-S1

<table>
<thead>
<tr>
<th>Penetratin</th>
<th>Mutated CP-d/n-ATF5-S1</th>
</tr>
</thead>
<tbody>
<tr>
<td>H$_2$N-RQIKIWFQNRRMKWKK</td>
<td>LEQRAEELARENEEELKEAELEGNAE</td>
</tr>
<tr>
<td>Penetratin</td>
<td>dominant/negative-sequence</td>
</tr>
<tr>
<td>H$_2$N-RQIKIWFQNRRMKWKK</td>
<td>GEGECQGGEARNREGKERAESV-COOH</td>
</tr>
<tr>
<td>Penetratin</td>
<td>dominant/negative-sequence</td>
</tr>
<tr>
<td>H$_2$N-RQIKIWFQNRRMKWKK</td>
<td>COOH</td>
</tr>
</tbody>
</table>

ATF5 leucine zipper truncated after first valine

B

T98G

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>45'</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP-d/n-ATF5-S1 50</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CP-d/n-ATF5-S1 100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CP-d/n-ATF5-S1 200</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Actin

MDA-MB-436

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>45'</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP-d/n-ATF5-S1 50</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CP-d/n-ATF5-S1 100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CP-d/n-ATF5-S1 200</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Actin

C

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>45'</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP-d/n-ATF5-S1 50</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CP-d/n-ATF5-S1 100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CP-d/n-ATF5-S1 200</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

ATF5

Actin

D

Relative protein expression (%)

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>15</th>
<th>45'</th>
<th>1.5h</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP-d/n-ATF5-S1 50</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CP-d/n-ATF5-S1 100</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CP-d/n-ATF5-S1 200</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

E

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>24h</th>
<th>72h</th>
</tr>
</thead>
<tbody>
<tr>
<td>T98G -</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>T98G 50</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 100</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 200</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
</tbody>
</table>

Mcl-1 mRNA (% of control)

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>24h</th>
<th>72h</th>
</tr>
</thead>
<tbody>
<tr>
<td>T98G -</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>T98G 50</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 100</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 200</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
</tbody>
</table>

Bcl-2 mRNA (% of control)

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>24h</th>
<th>72h</th>
</tr>
</thead>
<tbody>
<tr>
<td>T98G -</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>T98G 50</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 100</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 200</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
</tbody>
</table>

Usp9X mRNA (% of control)

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>24h</th>
<th>72h</th>
</tr>
</thead>
<tbody>
<tr>
<td>T98G -</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>T98G 50</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 100</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 200</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
</tbody>
</table>

F

All glioblastoma samples n=99
ATF5-amplified (≥ 2.2 copies) n=20
ATF5-deleted (≤ 1.8 copies) n=19

Log-rank p-values:
Amplified vs. deleted: 0.043
Amplified vs. all: 0.0266
Deleted vs. all: 0.012

G

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>24h</th>
<th>72h</th>
</tr>
</thead>
<tbody>
<tr>
<td>T98G -</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>T98G 50</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 100</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
<tr>
<td>T98G 200</td>
<td>+</td>
<td>+</td>
<td>#</td>
</tr>
</tbody>
</table>

Cellular viability (%)

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>0</th>
<th>50</th>
<th>100</th>
<th>200</th>
</tr>
</thead>
<tbody>
<tr>
<td>T98G -</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>T98G 50</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>T98G 100</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>T98G 200</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

H

Penetratin 200μM

CP-d/n-ATF5-S1 50μM

CP-d/n-ATF5-S1 100μM

CP-d/n-ATF5-S1 200μM

U87MG

Downloaded from clincancerres.aacrjournals.org on November 1, 2017. © 2016 American Association for Cancer Research.
### Figure 2

#### A

[Bar graph showing cellular viability (%)]

#### B

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>CP-d/n-ATF5-S1 [μM]</th>
<th>50</th>
<th>100</th>
<th>200</th>
</tr>
</thead>
<tbody>
<tr>
<td>U87MG</td>
<td>6.36</td>
<td>7.58</td>
<td>2.73</td>
<td>3.32</td>
</tr>
<tr>
<td></td>
<td>81.6</td>
<td>4.42</td>
<td>91.2</td>
<td>2.73</td>
</tr>
<tr>
<td></td>
<td>8.12</td>
<td>10.0</td>
<td>12.2</td>
<td>7.15</td>
</tr>
<tr>
<td>T98G</td>
<td>78.8</td>
<td>3.06</td>
<td>76.8</td>
<td>4.03</td>
</tr>
<tr>
<td></td>
<td>81.6</td>
<td>6.87</td>
<td>5.71</td>
<td>9.81</td>
</tr>
<tr>
<td></td>
<td>6.36</td>
<td>0.84</td>
<td>6.72</td>
<td>2.27</td>
</tr>
<tr>
<td>U251</td>
<td>86.7</td>
<td>3.92</td>
<td>64.4</td>
<td>20.1</td>
</tr>
<tr>
<td></td>
<td>2.45</td>
<td>4.54</td>
<td>2.94</td>
<td>4.11</td>
</tr>
<tr>
<td>LN229</td>
<td>90.2</td>
<td>2.82</td>
<td>96.9</td>
<td>2.03</td>
</tr>
<tr>
<td></td>
<td>4.53</td>
<td>0.57</td>
<td>8.19</td>
<td>0.60</td>
</tr>
<tr>
<td>MGPP-3</td>
<td>1.80</td>
<td>11.5</td>
<td>1.53</td>
<td>14.6</td>
</tr>
<tr>
<td></td>
<td>2.05</td>
<td>6.52</td>
<td>1.39</td>
<td>61.5</td>
</tr>
<tr>
<td>PC3</td>
<td>79.3</td>
<td>7.37</td>
<td>54.8</td>
<td>29.0</td>
</tr>
<tr>
<td></td>
<td>4.06</td>
<td>9.41</td>
<td>6.85</td>
<td>27.3</td>
</tr>
<tr>
<td>DU145</td>
<td>87.4</td>
<td>4.06</td>
<td>19.6</td>
<td>17.5</td>
</tr>
<tr>
<td></td>
<td>4.06</td>
<td>9.41</td>
<td>6.85</td>
<td>17.5</td>
</tr>
<tr>
<td>PANC-1</td>
<td>84.0</td>
<td>2.56</td>
<td>49.2</td>
<td>1.66</td>
</tr>
<tr>
<td></td>
<td>6.32</td>
<td>9.61</td>
<td>10.3</td>
<td>14.0</td>
</tr>
<tr>
<td>MDA-MB-436</td>
<td>82.9</td>
<td>1.20</td>
<td>72.3</td>
<td>3.38</td>
</tr>
<tr>
<td></td>
<td>2.10</td>
<td>7.41</td>
<td>2.49</td>
<td>11.2</td>
</tr>
<tr>
<td>H1975</td>
<td>85.3</td>
<td>5.15</td>
<td>80.2</td>
<td>6.11</td>
</tr>
<tr>
<td></td>
<td>1.06</td>
<td>3.56</td>
<td>0.64</td>
<td>9.68</td>
</tr>
<tr>
<td>A375</td>
<td>89.0</td>
<td>4.56</td>
<td>72.6</td>
<td>17.1</td>
</tr>
<tr>
<td></td>
<td>9.01</td>
<td>6.53</td>
<td>12.7</td>
<td>39.3</td>
</tr>
</tbody>
</table>

#### C

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>CP-d/n-ATF5-S1 [μM]</th>
<th>50</th>
<th>100</th>
<th>200</th>
</tr>
</thead>
<tbody>
<tr>
<td>HL-60</td>
<td>1.72</td>
<td>13.4</td>
<td>1.08</td>
<td>12.9</td>
</tr>
<tr>
<td></td>
<td>83.3</td>
<td>3.55</td>
<td>83.9</td>
<td>2.12</td>
</tr>
<tr>
<td></td>
<td>6.52</td>
<td>11.3</td>
<td>6.78</td>
<td>9.49</td>
</tr>
<tr>
<td>SU-DHL4</td>
<td>81.1</td>
<td>1.04</td>
<td>83.1</td>
<td>0.64</td>
</tr>
<tr>
<td></td>
<td>0.61</td>
<td>7.96</td>
<td>2.68</td>
<td>24.0</td>
</tr>
<tr>
<td>K562</td>
<td>88.4</td>
<td>3.05</td>
<td>65.1</td>
<td>8.16</td>
</tr>
<tr>
<td></td>
<td>6.52</td>
<td>13.2</td>
<td>19.6</td>
<td>10.6</td>
</tr>
<tr>
<td>Raji</td>
<td>78.2</td>
<td>2.10</td>
<td>69.2</td>
<td>0.57</td>
</tr>
</tbody>
</table>

#### D

[Graph showing propidium iodide uptake (%)]

#### E

[Bar graph showing cellular viability (%)]

#### F

[Graph showing propidium iodide uptake (%)]

#### G

[Graph showing cellular viability (%)]

#### H

[Graph showing JC-1 red fluorescence intensity]
Figure 3

A

<table>
<thead>
<tr>
<th></th>
<th>U87MG</th>
<th></th>
<th>T98G</th>
<th></th>
<th>H1975</th>
<th></th>
<th>PANC-1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>48h</td>
<td>72h</td>
<td>48h</td>
<td>72h</td>
<td>48h</td>
<td>72h</td>
<td>48h</td>
</tr>
<tr>
<td>CP-d/n-ATF5-S1</td>
<td>50 100 200</td>
<td>- 50 100 200</td>
<td>50 100 200</td>
<td>- 50 100 200</td>
<td>50 100 200</td>
<td>- 50 100 200</td>
<td>50 100 200</td>
</tr>
<tr>
<td>Mcl-1</td>
<td>1.6 .6 .1</td>
<td>1.2 .2 .2</td>
<td>1.8 .7 .2</td>
<td>1.8 .8 .8</td>
<td>1.1 .1 .8</td>
<td>1.2 .1 .9</td>
<td>1.3 .1 .1 .2</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>1.8 1.1 .4</td>
<td>1.9 2.3</td>
<td>1.7 1.5</td>
<td>1.1 .8 .1</td>
<td>1.1 .7 .2</td>
<td>1.1 .7 .6</td>
<td>1.2 1.1 .2</td>
</tr>
<tr>
<td>Bcl-xL</td>
<td>1.8 1.2 .6</td>
<td>1.4 .6 .1</td>
<td>1.7 1.5</td>
<td>1.1 .7 .3</td>
<td>1.1 .6 .4</td>
<td>1.1 .6 .4</td>
<td>1.1 .6 .4</td>
</tr>
<tr>
<td>Usp9X</td>
<td>1.9 .4 .4</td>
<td>1.6 .2 .1</td>
<td>1.2 .1 .01</td>
<td>1.3 1.1 .6</td>
<td>1.4 .5 .1</td>
<td>1.3 3.5 5.6</td>
<td>1.9 .5 .4</td>
</tr>
<tr>
<td>Bag3</td>
<td>1.8 1.9 .7</td>
<td>1.1 .3 .3</td>
<td>1.5 .6 .2</td>
<td>1.7 1.3</td>
<td>1.1 .6 .4</td>
<td>1.9 .5 .4</td>
<td>1.1 .8 .6</td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>T98G</th>
<th></th>
<th>U251</th>
<th></th>
<th>LN229</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>n.t.-siRNA</td>
<td>5.35</td>
<td>7.23</td>
<td>50.0</td>
<td>38.4</td>
<td>38.4</td>
<td>38.4</td>
</tr>
<tr>
<td>Usp9X-siRNA</td>
<td>2.39</td>
<td>10.2</td>
<td>87.2</td>
<td>19.1</td>
<td>9.43</td>
<td>4.75</td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th></th>
<th>U251</th>
<th></th>
<th>T98G</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>n.t.-siRNA</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Usp9X-siRNA</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Usp9X</td>
<td>1</td>
<td>.05</td>
<td>1</td>
<td>.06</td>
</tr>
<tr>
<td>cCP3</td>
<td>1</td>
<td>.04</td>
<td>1</td>
<td>.06</td>
</tr>
<tr>
<td>CP9</td>
<td>1</td>
<td>.06</td>
<td>1</td>
<td>.06</td>
</tr>
<tr>
<td>Bag3</td>
<td>1</td>
<td>.2</td>
<td>1</td>
<td>.1</td>
</tr>
<tr>
<td>Mcl-1</td>
<td>1</td>
<td>.2</td>
<td>1</td>
<td>.3</td>
</tr>
<tr>
<td>Mcl-1</td>
<td>1</td>
<td>.2</td>
<td>1</td>
<td>.3</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>1</td>
<td>.1</td>
<td>1</td>
<td>.9</td>
</tr>
<tr>
<td>Bcl-xL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 4

A

Cellular viability (%)

T98G

p<0.02

p<0.002

CP-d/n-ATF5-S1 - + - - + +
ABT263 - - + - + +
GX15-070 - - + - - +

B

Control
CP-d/n-ATF5-S1 100μM
mutated
CP-d/n-ATF5-S1 100μM

T98G

CP-d/n-ATF5-S1 + ABT263
Mutated CP-d/n-ATF5-S1 + ABT263

100 μm

C

Propidium iodide

Annexin V

CP-d/n-ATF5-S1 [μM]
100
0.5
0.5

ABT263 [μM]
-
-
1
1

T98G

3.67 7.06 10.3 29.2 8.13 11.2 4.18 18.9
84.4 4.91 40.3 20.3 50.2 30.5 18.8 58.2
2.86 4.18 8.73 21.9 2.35 11.2 5.68 53.2

LN229

88.8 4.14 58.2 11.2 80.3 6.16 26.9 14.3
3.03 14.5 1.43 16.3 6.85 28.7 2.26 35.4

PANC-1

73.5 8.97 48.4 33.9 53.1 11.4 34.8 27.6

CP-d/n-ATF5-S1 [μM]
100
0.5
0.5

ABT263 [μM]
-
-
1
1

SF188

2.83 22.6 5.01 40.0 2.81 39.3 4.38 60.2
71.7 2.87 40.9 14.0 51.4 6.52 13.7 21.8
0.34 8.91 0.53 32.6 1.55 33.8 2.45 24.8

K562

0.46 6.17 39.5 27.3 33.6 31.0 23.4 49.4

CP-d/n-ATF5-S1 [μM]
100
0.5
0.5

ABT263 [μM]
-
-
1
1

A375

8.27 4.62 0.36 15.3 1.72 10.3 0.59 24.4
94.8 7.73 54.6 29.9 70.6 11.4 32.1 42.9
11.9 1.66 14.8 12.6 5.80 7.22 12.2 24.4

NCH644

80.4 6.00 48.0 24.6 59.8 27.2 31.4 32.0

D

E

Fraction of annexin V- and PI-positive cells in %

CP-d/n-ATF5-S1

Mutated

CP-d/n-ATF5-S1

ABT263

T98G

LN229

SF188

NCH644

PANC-1

A375

K562

F

T98G

CP-d/n-ATF5-S1-

Mutated

ABT263

Mcl-1

Bcl-2

Bcl-xL

Actin

CP9

CF

Downloaded from clincancerres.aacrjournals.org on November 1, 2017. © 2016 American Association for Cancer Research.
Figure 5

A

T98G

Cellular viability (%)

CP-d/n-ATF5-S1

mutated

TRAIL 1.25

TRAIL 2.5

TRAIL 5

B

T98G

Control

CP-d/n-ATF5-S1 100μM

mutated CP-d/n-ATF5-S1 100μM

TRAIL 5ng/ml

CP-d/n-ATF5-S1 + TRAIL

Mutated CP-d/n-ATF5-S1 + TRAIL

C

D

E

F

G

H

I

J

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 28, 2016; DOI: 10.1158/1078-0432.CCR-15-2827

Downloaded from clincancerres.aacrjournals.org on November 1, 2017. © 2016 American Association for Cancer Research.
Figure 6

A. GBM12

B. A375

Control

CP-d/n-ATF5-S1 50mg/kg i.p.

Days

Tumor cell implantation

Day 18

Tumor volume (mm³)

Control CP-d/n-ATF5-S1

Day 35

Tumor volume (mm³)

Control CP-d/n-ATF5-S1

Tumor cell implantation

50mg/kg i.p.

Days

Control CP-d/n-ATF5-S1

Day 40

Tumor volume (mm³)

Control CP-d/n-ATF5-S1

ABT263 25mg/kg i.p.

Control CP-d/n-ATF5-S1 (CP)

ABT263 (A)

CP + A

24 days after tumor cell implantation
A synthetic cell-penetrating dominant-negative ATF5 peptide exerts anti-cancer activity against a broad spectrum of treatment resistant cancers


Clin Cancer Res Published OnlineFirst April 28, 2016.

Updated version
Access the most recent version of this article at:

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2016/05/27/1078-0432.CCR-15-2827.DC2

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.